(Q72843371)
Statements
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects (English)
J A Sosman
G R Weiss
K A Margolin
F R Aronson
M Sznol
M B Atkins
K O'Boyle
R I Fisher
D H Boldt